Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
- 12 January 2011
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 13 (4), 357-365
- https://doi.org/10.1111/j.1463-1326.2011.01359.x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and ExerciseDiabetes Care, 2010
- Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- A Study of Dapagliflozin in Patients With Type 2 Diabetes Receiving High Doses of Insulin Plus Insulin SensitizersDiabetes Care, 2009
- Renal sodium–glucose transport: role in diabetes mellitus and potential clinical implicationsKidney International, 2009
- Glucose Control by the Kidney: An Emerging Target in DiabetesAmerican Journal of Kidney Diseases, 2009
- Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes MellitusCancer Cell, 2009
- Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of TherapyDiabetes Care, 2009
- Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 DiabetesDiabetes Care, 2008
- Dapagliflozin, a Selective SGLT2 Inhibitor, Improves Glucose Homeostasis in Normal and Diabetic RatsDiabetes, 2008
- Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 DiabetesJournal of Medicinal Chemistry, 2008